Publication details
FoxO1 signaling in B cell malignancies and its therapeutic targeting.
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | FEBS Letters |
| MU Faculty or unit | |
| Citation | |
| Web | https://febs.onlinelibrary.wiley.com/doi/epdf/10.1002/1873-3468.15057 |
| Doi | http://dx.doi.org/10.1002/1873-3468.15057 |
| Keywords | AS1842856; B cell development; B cell malignancies; chroniclymphocytic leukemia; cpd10; FoxO1; FoxO1 inhibitor; leukemia;lymphoma; targeted therapy |
| Attached files | |
| Description | FoxO transcription factors (FoxO1, FoxO3a, FoxO4, FoxO6) are a highlyevolutionary conserved subfamily of the ‘forkhead’ box proteins. They havetraditionally been considered tumor suppressors, but FoxO1 also exhibitsoncogenic properties. The complex nature of FoxO1 is illustrated by its vari-ous roles in B cell development and differentiation, immunoglobulin gene rear-rangement and cell-surface B cell receptor (BCR) structure, DNA damagecontrol, cell cycle regulation, and germinal center reaction. FoxO1 is tightlyregulated at a transcriptional (STAT3, HEB, EBF, FoxOs) andpost-transcriptional level (Akt, AMPK, CDK2, GSK3, IKKs, JNK, MAP-K/Erk, SGK1, miRNA). In B cell malignancies, recurrent FoxO1 activatingmutations (S22/T24) and aberrant nuclear export and activity have beendescribed, underscoring the potential of its therapeutic inhibition. Here, wereview FoxO1’s roles across B cell and myeloid malignancies, namely acutelymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lym-phocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B cell lym-phoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL),Hodgkin lymphoma (HL), and multiple myeloma (MM). We also discuss pre-clinical evidence for FoxO1 targeting by currently available inhibitors(AS1708727, AS1842856, cpd10). |
| Related projects: |